A CK2-dependent mechanism for degradation of the PML tumor suppressor

被引:251
作者
Scaglioni, Pier Paolo
Yung, Thomas M.
Cai, Lu Fan
Erdjument-Bromage, Hediye
Kaufman, Andrew J.
Singh, Bhuvanesh
Teruya-Feldstein, Julie
Tempst, Paul
Pandolfi, Pier Paolo
机构
[1] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, Sloan Kettering Inst, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Program Mol Biol, Sloan Kettering Inst, New York, NY 10021 USA
[5] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA
关键词
D O I
10.1016/j.cell.2006.05.041
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The PML tumor suppressor controls key pathways for growth suppression, induction of apoptosis, and cellular senescence. PML loss occurs frequently in human tumors through unknown posttranslational mechanisms. Casein kinase 2 (CK2) is oncogenic and frequently upregulated in human tumors. Here we show that CK2 regulates PML protein levels by promoting its ubiquitin-mediated degradation dependent on direct phosphorylation at Ser517. Consequently, PML mutants that are resistant to CK2 phosphorylation display increased tumor-suppressive functions. In a faithful mouse model of lung cancer, we demonstrate that Pml inactivation leads to increased tumorigenesis. Furthermore, CK2 pharmacological inhibition enhances the PML tumor-suppressive property in vivo. Importantly, we found an inverse correlation between CK2 kinase activity and PML protein levels in human lung cancer-derived cell lines and primary specimens. These data identify a key posttranslational mechanism that controls PML protein levels and provide therapeutic means toward PML restoration through CK2 inhibition.
引用
收藏
页码:269 / 283
页数:15
相关论文
共 44 条
  • [11] Development of a flexible and specific gene delivery system for production of murine tumor models
    Fisher, GH
    Orsulic, S
    Holland, E
    Hively, WP
    Li, Y
    Lewis, BC
    Williams, BO
    Varmus, HE
    [J]. ONCOGENE, 1999, 18 (38) : 5253 - 5260
  • [12] The function of PML in p53-dependent apoptosis
    Guo, A
    Salomoni, P
    Luo, JY
    Shih, A
    Zhong, S
    Gu, W
    Pandolfi, PP
    [J]. NATURE CELL BIOLOGY, 2000, 2 (10) : 730 - 736
  • [13] Loss of the tumor suppressor PML in human cancers of multiple histologic origins
    Gurrieri, C
    Capodieci, P
    Bernardi, R
    Scaglioni, PP
    Nafa, K
    Rush, LJ
    Verbel, DA
    Cordon-Cardo, C
    Pandoli, PP
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (04): : 269 - 279
  • [14] Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis
    Hayakawa, F
    Privalsky, ML
    [J]. CANCER CELL, 2004, 5 (04) : 389 - 401
  • [15] CK2 is a C-terminal IκB kinase responsible for NF-κB activation during the UV response
    Kato, T
    Delhase, M
    Hoffmann, A
    Karin, M
    [J]. MOLECULAR CELL, 2003, 12 (04) : 829 - 839
  • [16] A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1
    Keller, DM
    Zeng, XY
    Wang, Y
    Zhang, QH
    Kapoor, M
    Shu, HJ
    Goodman, R
    Lozano, G
    Zhao, YM
    Lu, H
    [J]. MOLECULAR CELL, 2001, 7 (02) : 283 - 292
  • [17] KOKEN MHM, 1995, ONCOGENE, V10, P1315
  • [18] Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor α degradation
    Lallemand-Breitenbach, V
    Zhu, J
    Puvion, F
    Koken, M
    Honoré, N
    Doubeikovsky, A
    Duprez, E
    Pandolfi, PP
    Puvion, E
    Freemont, P
    de Thé, H
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (12) : 1361 - 1371
  • [19] Protein kinase CK2 in mammary gland tumorigenesis
    Landesman-Bollag, E
    Romieu-Mourez, R
    Song, DH
    Sonenshein, GE
    Cardiff, RD
    Seldin, DC
    [J]. ONCOGENE, 2001, 20 (25) : 3247 - 3257
  • [20] LAVAU C, 1995, ONCOGENE, V11, P871